Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study. (September 2022)

• Record Type: Journal Article
• Authors: Dimitrakopoulos, Foteinos-Ioannis; Mountzios, Giannis; Christopoulos, Petros; Papastergiou, Thomas; Elshiaty, Mariam; Daniello, Lea; Zervas, Elefterios; Agelaki, Sofia; Samantas, Epaminondas; Nikolaidi, Adamantia; Athanasiadis, Ilias; Baka, Sofia; Syrigos, Konstantinos; Christopoulou, Athina; Lianos, Evangelos; Samitas, Konstantinos; Tsoukalas, Nikolaos; Perdikouri, Eleni-Isidora; Oikonomopoulos, George; Kottorou, Anastasia; Kalofonou, Foteini; Makatsoris, Thomas; Koutras, Angelos; Megalooikonomou, Vasileios; Kalofonos, Haralabos
• Is Part Of: Therapeutic advances in medical oncology. Volume 14(2022)
• Publication Date: 2022-09
• Subjects: biomarker -- nivolumab -- NSCLC -- Patras Immunotherapy Score -- pembrolizumab -- PIOS; Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.994005
• DOI: 10.1177/17588359221122728
• Languages: English
• ISSNs: 1758-8340

Abstract

Background: Recently, the Patras Immunotherapy Score (PIOS) has been developed to estimate the survival benefit of patients with advanced non-small-cell lung cancer (aNSCLC) treated with nivolumab or pembrolizumab. The aim of this study was to validate the clinical value of PIOS in an external cohort of aNSCLC patients. Methods: PIOS is a baseline formula produced by the combination of performance status, body mass index, age and line of treatment. In this multicentre study, 626 patients with confirmed NSCLC pathology, who had been treated with nivolumab or pembrolizumab, as well as 444 patients with aNSCLC, who had been managed with chemotherapy alone, were retrospectively enrolled. Predictive and prognostic values of PIOS were finally evaluated. Results: Patients treated with immunotherapy and higher PIOS score had an improved progression-free survival not only in univariate [hazard ratio (HR) = 0.621, p = 0.001], but also in multivariable analysis (HR = 0.651, p = 0.003). In addition, improved overall survival with increasing PIOS score was also observed (HR = 0.608, p < 0.001) with this association remaining statistically significant after adjusting for programmed-cell death ligand 1 (PD-L1) expression (HR = 0.620, p < 0.001). In addition, patients with disease progression (PD) had lower scores compared to those with stable disease (SD), partial response (PR) or complete response (CR) in a two-tier model ( p < 0.001) as well as in a four-tier model (PD, SD, PR and CR; p < 0.001). Prognostic significance of PIOS score also persisted using a binary logistic regression analysis, adjusted for disease stage and PD-L1 status ( p = 0.002, odds ratio: 0.578). Contrarily, PIOS had no prognostic significance in the chemotherapy group; however, upon combined analysis of the two cohorts, PIOS was found to have a significant interaction with the type of treatment (HR = 0.066 with p < 0.001), confirming its predictive value for immunotherapy. Conclusions: This study provides further validation of PIOS in aNSCLC patients treated with anti-PD-1 monotherapy.